For all the reported issues facing Medtronic (NYSE: MDT) the company when it comes to diabetes anyway these issues aren’t hurting results. Per the results released this morning; “Diabetes Group worldwide fourth quarter revenue of $645 million increased 26.0 percent, or 21.3 percent on a constant currency basis.” In a surprise move the company noted they now have over 70,000 patients on the 670G, typically the company is silent when it comes to releasing patient count so this move is notable.
Sadly, the company continues to insist they can compete in the stand-alone CGM market . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.